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“Really? – a chicken herpesvirus? I didn’t even know that herpes exist in chickens”. 
During my time as a PhD student, I often had to convince people of the importance and 
relevance of our work and how it contributes to a better understanding not only of the virus-
host interplay in avian species, but also of virus-induced cancers in general.  
Chickens have served as model organisms for centuries: The field of embryology is based on 
discoveries made in chickens [1], a species that also vastly contributed to our understanding 
of the major concepts in immunology, genetics, cell biology, and, last but not least, virology 
and cancer [2]. Moreover, poultry (and especially chicken) production and consumption will 
likely continue to grow and strengthen its dominant position within the meat complex. Poultry 
meat already accounts for almost 45% of all meat that is consumed worldwide [3] and is one 
of the most important sources of animal protein. Research into poultry diseases will therefore 
improve the quality of poultry farming particularly in developing countries. 
Viruses are incredible little pathogens– there is much more to add to this. But just consider 
this: there are approximately 1 million virus particles per milliliter of seawater [4]. Isn’t that 
fascinating enough already? As one of nine virus orders that have been identified yet and 
classified by the International Committee on Taxonomy of Viruses (ICTV) [5], herpesviruses 
have many very intriguing features including the establishment of lifelong infections termed 
latency, infections of both vertebrate and non-vertebrate species and associations with various 
cancers [6-8]. 
One of those herpesviruses is Marek’s disease virus, an important poultry pathogen that is 
able to rapidly transform host cells into cancer cells [9]. 
My PhD thesis, entitled “Marek’s disease virus-host interplay: novel insights into lymphocyte 
infections of an oncogenic avian herpesvirus” combines the aforementioned research areas 







6.1  Herpesviruses 
Herpes is forever! This expression is based on the fact that herpesviruses have the ability to 
remain in the host for life by establishing a latent phase of infection. This hallmark of 
herpesvirus infections ensures lifelong virus persistence and escape from the host immune 
system. The latent virus can occasionally reactivate resulting in disease and virus spread. 
Other common features of herpesviruses are their host specificity and a long evolutionary 
history of coevolution with their host species, and they are enveloped viruses that possess a 
large DNA genome [10].  
The classification of herpesviruses is complex and herpesviruses are found in mammals and 
birds, but also in fish, frogs, reptiles, and so far a single herpesvirus in bivalves (molluscs) [11]. 
All herpesviruses are assigned to the order Herpesvirales with three distinct families: the 
Herpesviridae (that infect mammals, birds, and reptiles), the Alloherpesviridae in fish and 
amphibians, and the Malacoherpesviridae in invertebrates. Furthermore, the family of 
Herpesviridae is divided into the subfamilies Alpha-, Beta- and Gammaherpesvirinae with 
prominent members like the human herpesviruses such as herpes simplex and Epstein-Barr 
virus. With steadily increasing numbers of identified virus species, the Herpesviridae family 
consists of more than 200 members [12]. More and more full genome sequences are available 
for a tremendous number of herpesviruses that need to be classified. For example, the 
International Committee on Taxonomy of Viruses (ICTV) Herpesvirales Study Group currently 
proposes the classification of 18 new species into existing genera [13]. 
To date, 9 human herpesviruses exist [10] and among those are representatives from each of 
the three subfamilies: Herpes simplex viruses 1 and 2 (HSV-1 and HSV-2) varicella-zoster 
virus (VZV), Epstein–Barr virus (EBV), human cytomegalovirus (HCMV), human herpesvirus 
6A and 6B (HHV-6A and HHV-6B), human herpesvirus 7 (HHV-7), and Kaposi's sarcoma-
associated herpesvirus (KSHV). Among the veterinary herpesviruses, the most prominent 
members are viruses that infect pigs (pseudorabies), cattle (BoHV), horses (EHV), cats (FHV) 
and avian species (see below). 
The most important avian herpesviruses that causes dramatic losses in poultry industry 
worldwide of up to 1-2 billion US-dollar annually, is Marek’s disease virus (MDV) [14]. Besides 
MDV, other avian herpesviruses like infectious laryngotracheitis virus (ILTV), herpesvirus of 
turkeys (HVT), Pacheco's parrot disease virus (PsHV-1), pigeon herpesvirus (CoHV-1), and 
14 
 
duck plague virus (AnHV-1) are of importance to veterinarians, poultry industry and bird 
keepers [15]. 
Herpesviruses are enveloped viruses and their shape is described as spherical to pleomorphic. 
They possess an icosahedral symmetry and usually have a diameter of 150 – 200nm in size. 
The lipid envelope bilayer is obtained by budding at an intracellular membrane. It embeds 
several different protruding glycosylated envelope proteins that form spike structures on the 
virus surface. The envelope surrounds an outer and inner amorphous protein coat, the 
tegument. The next layer, the nucleocapsid, consists of 162 capsomers of which 150 are 
hexameric and 12 are pentameric. The nucleocapsid protects the virus core that contains a 
linear double stranded DNA, which is monopartite and 120 – 240 kpb in size depending on the 
herpesvirus species [10-12]. 
 
 
Figure 1: Structure of the alphaherpesvirinae virion 
Herpesviruses are enveloped, spherical to pleomorphic viruses with an icosahedral 
symmetry and a diameter of 150 – 200nm. The lipid envelope embeds several different 
glycoprotein complexes (envelope proteins) and surrounds an outer and inner 
amorphous tegument. The nucleocapsid consists of 162 capsomers (150 are hexameric 
and 12 pentameric) and protects the linear double stranded DNA, which is monopartite 






Figure 2: The herpesvirus life cycle 
 A herpesvirus infection (in this case exemplarily depicted for HSV) starts with entry of the 
virus by fusion of the viral envelope with the host membrane (i). In the host cell, the capsid 
is then transported to the nucleus along microtubules (ii) and the viral genome is released 
into the nucleus through nuclear pores (iii). Upon circularization of the viral DNA, the virus 
genome is replicated in the nucleus as concatamers, followed by the procapsid (pc) 
formation and subsequent encapsidation of cleaved DNA (iv). Capsids exit the host cell 
nucleus by an envelopment and de-envelopment mechanism in the nuclear membrane 
(v). Capsids are then transported to the locus of virion assembly (vi). Assembly includes 
a secondary envelopment and tegumentation and occurs close to the cell surface by 
budding into cellular vesicles. These vesicles originate from the Golgi complex (vii). 
Virions are released from the cell by vesicle fusion with the host cell plasma membrane 
(viii). MTOC = microtubule organizing center, ER = endoplasmic reticulum, mc = mature 
capsid. (Image and legend modified from [16]) 
 
6.2  Herpesvirus replication 
Herpesvirus replication has been most extensively studied for the prototype members of the 
human herpesviruses, especially in HSV-1 [17]. The replication cycle of herpesviruses starts 
with cell entry by attachment of viral envelope glycoproteins to the host cell membrane and 
subsequent fusion. Upon fusion, the nucleocapsid penetrates the host plasma membrane. It 
subsequently enters the cytoplasm and is transported to the nucleus. There, the viral genome 
is released into the nucleus through the nuclear pore. Upon circularization of the DNA, the 
virus genome is transcribed in the nucleus as concatamers, a process that is followed by the 
procapsid formation and encapsidation of cleaved DNA. Herpesvirus procapsids are 
assembled in the nucleus of infected cells and final maturation of the virion occurs in the 
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cytosol. Capsids exit the nucleus by a primary envelopment and de-envelopment mechanism 
at the inner and outer nuclear membrane. The mature capsids are then transported to the site 
of virion assembly where it acquires the final tegument and the secondary envelopment. These 
steps of the virus life cycle occur close to the cell surface by budding into cellular vesicles 
originating from the Golgi complex. Virions are released from the cell by fusion of these cellular 
vesicles with the plasma membrane [16, 18]. 
The virus of interest in this thesis is MDV, an important avian herpesvirus that causes a 
devastating malignant tumor disease. The MDV story began in the early years of the  
20th century…: 
 
6.3  Marek’s disease virus history 
A Hungarian veterinary doctor, József Marek, discovered a disease in chickens in 1907. He 
examined chickens that suffered from severe paralysis of the legs and wings and described it 
as a polyneuritis after post mortem observation of thickened plexus and sciatic nerves [19]. 
His findings were published in the German journal “Deutsche Tierärztliche Wochenschrift” (Fig. 
3) and set the basis for more than 100 years of MDV research with all its success stories and 
pitfalls. Similar reports were published in the following years by Kaupp (USA) and van der 
Walle (The Netherlands) [20, 21]. However, it took more than 20 years to link this polyneuritis 
disease to tumors. This link was confirmed by Pappenheimer et al. in 1929 [22, 23]. Following 
their findings, the disease terms that were previously used became unsatisfactory. A new term 
that Pappenheimer et al. suggested was “neurolymphomatosis gallinarum”, which described 




Figure 3: First MDV publication (J. Marek, 1907)  
“Multiple Nervenentzündung (Polyneuritis) bei Hühnern” – published in the Deutsche 
Tierärztliche Wochenschrift in 1907 by the veterinary clinician and pathologist Dr. Josef 
Marek. He was professor and head of the Department of Veterinary Medicine at the Royal 
Hungarian Veterinary School in Budapest, Hungary. (Image from [24]) 
 
MDV research developed and faced different challenges: for example, there were extensive 
discussions about the correct diagnosis of different lymphomas of MD and lymphoid leucosis, 
such as avian leucosis that is a retroviral disease and causes a variety of neoplastic conditions 
in chickens. 
In the early 1960’s, Sevoian and Chamberlain provided evidence of the transmissibility of MD 
between chickens. To do so, they inoculated healthy chickens with blood, tissue and tumor 
cell suspensions from infected birds [25]. A few years later, in 1967, Churchill and Biggs 
identified a herpesvirus as the causative agent of MD [26]. Only then, the virus was designated 
as Marek’s disease virus [27]. Over time, Marek's disease developed from a rather mild 
disease into a highly contagious lymphoproliferative disorder of chickens with a clinical picture 
that has changed dramatically since its initial recognition. Additional to the neurological signs 
and tumors, very virulent plus strains can nowadays cause severe brain edemas and acute 
deaths, and tumor lesions even in vaccinated chickens [28-31]. There is comprehensive 
evidence that the increasing virulence of MDV stains emerged independently in North America 




6.4  General facts and MDV replication cycle 
6.4.1  MDV 
MDV belongs to the genus Mardivirus in the subfamily Alphaherpesvirinae in the order 
Herpesvirales. Five different serologically related but distinct virus species belong to this 
genus: Gallid alphaherpesvirus 2 (GaHV-2/MDV), Gallid alphaherpesvirus 3 (GaHV-3/MDV 
serotype 2), the Meleagrid alphaherpesvirus 1 (HVT), and two viruses of quail and pigeons 
(Anatid alphaherpesvirus 1 and Columbid alphaherpesvirus 1) (ICTV Virus Taxonomy: 2017 
Release). MDV are highly contagious viruses that cause lymphoma and various other 
symptoms, whereas the natural occurring but non-pathogenic serotype 2-strains can be used 
as live vaccines to protect from Marek's disease virus infections (same as the also closely 
related HVT) [33]. Despite of the widespread use of live attenuated vaccines, MDV remains a 
major pathogen of poultry and causes approximately one to two billion euros loss worldwide 
every year [14]. Even though Marek’s disease vaccines are highly effective in minimizing 
commercial losses due to tumor formations and neurological deficits, they do not provide 
sterilizing immunity and thereby allow a continued evolution of MDV strains in vaccinated 
chickens [34-37]. This gradual evolution towards a greater virulence allows MDV to overcome 
the protection of current vaccines and poses a serious threat to poultry production. 
Furthermore, MDV is important for biomedical research as it is used as a versatile and 
convenient small-animal model for virus-induced tumor formation [9]. 
 
6.4.2  Clinical symptoms 
The clinical picture of the disease can be described as follows: chickens infected with MDV will 
likely show clinical signs with several appearances, including neurologic, visceral, ocular and 
cutaneous forms [38]. Neurological manifestations may vary according to the nerve(s) affected 
and paralysis of one or more of the extremities can be observed. The wings can also be 
affected. Torticollis can appear due to an inflammation of nerves controlling the neck and vagal 
involvement will lead to dilatation of the crop. Visceral lesions derive from T cell lymphoma 
metastases and can occur in nearly every visceral organ. However, mostly heart, liver, spleen, 
kidneys, proventriculus, testes/ovaries, and muscles are affected [37]. In the ocular and 
cutaneous forms, blindness may occur (caused by iridocyclitis) and lymphoid proliferation in 
skin and feather follicles can happen, respectively [14, 39]. In MDV infections, nonspecific 
signs such as weight loss, paleness, anorexia, and diarrhea are also observed. Of note is, that 
MDV infections can lead to an acute mortality syndrome, where affected birds die with an early 




                        
Figure 4: Clinical MDV signs 
Clinical signs that are observed in MDV infected chickens are torticollis, ataxia, and 
paralysis of the legs and wings (due to an enlargement of peripheral nerves). MDV 
infections may also cause increased mortality in chicklets of 1–2 weeks of age and 
lymphomatous lesions can occur in multiple organs such as the ovary, liver, spleen, 
kidneys, lungs, heart, proventriculus and skin - depending on the strain of MDV. 
 
6.4.3  MDV replication 
MDV has a complex replication cycle that can be divided in a productive (lytic) replication stage 
and a latent stage of infection [14]. As other herpesviruses, MDV can establish latency, 
whereby latency is described as the ability of the virus to lie dormant (latent) within a cell [40]. 
The widely accepted Cornell model of the MDV life cycle starts with an early macrophage 
infection in the lung after inhalation of airborne cell-free virus particles from a contaminated 
environment [41]. These cells transport the virus to the primary lymphoid organs, the bursa of 
Fabricius, thymus and spleen. In these organs, the virus is transferred to B cells, which are the 
primary target cells for lytic replication in an infected chicken. The massive lytic replication in 
B cells (and later also in T cells) leads to an immunosuppression which increases the 
susceptibility of infected birds to other infectious agents [42]. The infection of B cells results in 
the activation and infection of CD4+ T cells by direct cell-to-cell transfer [43-45]. In activated 
CD4+ T cells, the virus is able to establish a latent infection in which it integrates its genome 
into host telomeres. Virus integration is facilitated by viral telomeric repeats (TMRs) [46-48]. 
Consequently, those T cells can be transformed by the virus and MDV-transformed cells 
possess a regulatory T cell phenotype based on their cytokine and cell surface marker 
expression profiles [49, 50]. The latent virus can occasionally reactivate resulting in lytic 
replication of the virus. The efficiency of lymphoma formation is dependent on the virus strain 
and the genetic background of the chickens [51]. In order to be transmitted to other chickens, 
infected CD4+ T cells transport the virus to the skin where it replicates in the feather follicle 
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epithelial (FFE) cells. Those FFE cells release keratin-encased virus into the environment by 
desquamation of chicken dander [43, 52]. 
 
 
Figure 5: The MDV life cycle 
Infection is initiated by the inhalation of cell-free MDV. Macrophages and dendritic cells 
are thought to transfer the virus to lymphoid organs such as spleen, thymus and bursa, 
where the virus infects and replicates in B cells. This leads to either B cell apoptosis or a 
subsequent infection of activated T cells. MDV is able to establish latency in infected  
T cells with virus reactivation or T cell transformation as two possible consequences. 
Latently infected T cells can transport the virus to the skin and the feather follicle epithelia 
(FFE), where cell free MDV is generated. MØ: macrophages; DC: dendritic cells; FFE: 
feather follicle epithelium; MDV: Marek’s disease virus. (Image was kindly provided from 
Dr. A. Greco and modified from [53]) 
 
6.5  MDV genome structure 
MDV possesses a rather large genome size of approximately 180kbp, (from 
https://www.ncbi.nlm.nih.gov/genome/viruses/, effective July 2018). The MDV genome is a 
class E genome that consists of a unique long (UL) and a unique short (US) segment, each 
flanked by inverted terminal (TRL and TRS) and internal (IRL and IRS) repeats [54]. MDV and 
the closely related GaHV-3 and HVT share significant sequence homology throughout the 
genome except within the repeat-long regions. Both unique regions mainly encode for genes 
that are conserved amongst alphaherpesviruses and are involved in DNA replication and 
production of progeny virus. The four repeat regions contain most of the MDV-specific genes 
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that encode for proteins or RNAs that are important for pathogenesis, cellular tropism, 
tumorigenesis and latency [55, 56].  
 
Figure 6: The MDV genome structure 
The entire MDV genome is predicted to be about 180kbp in size. It is organized like a 
typical α-herpesvirus with unique long (UL) and unique short (US) sequences flanked by 
terminal (TRL and TRS) and internal (IRL and IRS) inverted repeat regions. 
 
MDV encodes for more than 100 annotated genes [54, 55]. Most of them annotated based on 
their homology to HSV-1 genes. However, MDV also carries a number of open reading frames 
(ORFs) that have not yet been investigated - neither regarding their coding potentials, nor 
regarding their transcriptional and translational products [57]. We and others are currently 
investigating these genes in order to better understand the complex MDV replication cycle, 
genome integration, and MDV-induced tumor formation. 
 
6.6  MDV virulence factors 
There are several viral factors that are involved in MDV pathogenesis (Table 1) and our 
knowledge of them is steadily increasing. Especially in the last years, MDV research made 
progress in terms of identification of mechanistic descriptions of these viral factors. The key 
player in MDV pathogenesis and probably the most studied protein in the MDV field is the 
major oncoprotein Meq. Meq is a basic leucine zipper protein (bZIP), which shows homology 
to the human proto-oncoproteins Fos and Jun [58]. Furthermore, MDV encodes for other 
proteins that influence disease progression at different stages: vIL8 [44, 59, 60], RLORF4 [61], 








Virulence factor Function 
meq 
Major oncogene, DNA‐binding transcription factor related to bZIP 
proteins 
RLORF4 Deletion results in attenuation in vivo 
vIL-8 Secreted CXC chemokine involved in attraction of target cells 
pp14 Neurovirulence factor 
pp38 Deletion severely impairs tumor formation 
miRNAs 
Non-coding RNAs that regulate gene expression at the post-
transcriptional level 
vTR 
Viral telomerase RNA homologue that is crucial for efficient MDV-
induced lymphoma formation 
TMR Facilitate genome integration 
 
Table 1: MDV virulence factors 
Important MDV gene products involved in pathogenesis. 
 
MDV also encodes for non-coding RNAs that are essential for pathogenesis and 
tumorigenesis. Besides several MDV-encoded micro RNAs that are located in the repeat 
regions of the virus genome [71, 72], the virus possesses a viral telomerase RNA (vTR) has 
an 88% sequence identity to the cellular TR in chickens (chTR) [73-75]. vTR was found to be 
the most abundant viral transcript detected in MDV tumor cells and is crucial for MDV-induced 
malignant transformation [75]. That might be due to an interaction with the chicken telomerase 
reverse transcriptase subunit (TERT) and that interaction could facilitate an enhanced 
telomerase activity [73], which almost always correlates with cell immortalization [76]. In order 
to maintain the virus genome in latently infected host cells and tumor cells, MDV integrates 
into the telomeres of host chromosomes using viral telomeric repeats (TMRs). Those TMRs 
(TTAGGG repeats) are present in the so-called a-like sequences that localize at both ends of 
the virus genome and at the junction between the IRL-IRS [46, 47, 77, 78]. Although much has 
been done to unravel underlying mechanisms and functions of MDV pathogenesis factors, all 
those factors, and probably more (maybe even unknown ones) have to be further 
characterized and studied to get a full overview of MDV infections as lytic and latent stages, 
and a more detailed knowledge of the cellular transformation.  
 
6.7  Immunity and resistance to MDV 
Several innate and adaptive immune responses are mounted after MDV infection or 
vaccination. B cells are involved in humoral immunity, which plays a minor role in the protection 
against MDV since the virus is highly cell-associated. Maternal antibodies provide little 
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protection in the first weeks of life [79] and only delay MD development in terms of clinical 
symptoms and tumor formation. On the other hand, maternal antibodies can also weaken 
immune responses to MDV vaccination, thereby decreasing vaccine efficiency [80]. A far 
stronger and more reliable immune response is mediated by cellular immunity: T cell-mediated 
immunity is mainly driven by CD8+ cytotoxic T cells, which are primed against late viral 
glycoproteins [81], but also against immediate early and early MDV proteins [82]. Additionally, 
CD4+ T cells are most likely involved and further work needs to confirm the exact role of CD4+ 
and CD8+ T cell subsets and their responses against MDV infections [80]. Macrophages and 
natural killer cells as major cellular components of the innate immune system are also thought 
to contribute to immunity against MDV [83-85].  
The MDV vaccination history started with the launch of an HVT-based vaccine (FC126 strain) 
in the early 1970s [86, 87]. This was the first antiviral vaccine that efficiently prevented cancer 
in any species [35]. However, in the late 1970s, the HVT vaccine was no longer protective 
since more virulent emerging field strains emerged. Realizing the need for new MDV vaccines, 
Schat and Calnek isolated a non-pathogenic serotype 2 strain (SB1). A bivalent vaccine 
composed of HVT and SB1 [88] greatly improved protection from those new field strains and 
is referred to as the second generation of MDV vaccines. The third generation vaccine, 
CVI988, which still is the gold standard vaccine against MDV [87], was established and tested 
by Dr. Rispens of the Dutch Central Veterinary Institute [89, 90]. With the second generation 
and third generation vaccines, the virus was controlled and did usually not cause pathogenesis 
in vaccinated flocks (Fig. 7). CVI988 is currently used worldwide to protect long-lived chickens 
such as layers and breeders. Apparently, more doses of MDV vaccines are administered than 
any other, regardless of the species [91]. It is very efficient in the prevention of MD, but fails to 
provide sterilizing immunity and thereby allows virulent field strains to spread in infected 
chicken flocks [35]. The emergence of more virulent MDV field strains appears to coincide with 
the introduction of extensive vaccination programs (Fig 7). Considering this constant evolution 
of MDV strains towards a greater virulence, the disease remains a threat to poultry production 
[35-37, 92, 93] (Fig. 7). Besides the epidemiological data, this theory has also been 
investigated experimentally: it has been shown that MDV vaccines that do not prevent virus 
transmission can contribute to the development of highly pathogenic MDV that can cause more 
severe disease in unvaccinated chickens [93]. Hence, the development of new vaccines that 




Figure 7: Evolution of MDV towards greater virulence 
Increasing virulence of MDV field strains and introduction of the different MDV vaccines 
from 1940 to the present (Image adapted from [35]). 
 
Recent findings in avian immunology suggested that the chicken major histocompatibility 
complex class 1 (MHC-1) gene plays a crucial role in the immune response of the infected 
chicken towards MDV [51, 94-97]. Of note is, that (in contrast to humans), chicken only express 
a single predominant MHC-1 haplotype [96]. This single predominant haplotype has a very 
strong association with resistance and susceptibility to MDV: for example, it has been 
observed, that the MHC-1 B21 haplotype is much more resistant to MDV infections than  
B19 [98]. It is believed that the MHC-1 haplotypes can be ranked in terms of MDV susceptibility 
and resistance, respectively [99, 100] and interestingly, MHC haplotypes also influence the 
efficacy of vaccination against MDV [101]. More data is needed to elucidate the way in which 
the chicken MHC-1 contributes to disease resistance. 
 
6.8  Transgenic chickens 
Since the first report of transgenic animals in 1981 [102, 103], the field has vastly expanded 
and transgenic animals have become indispensable in today's biomedical research. However, 
research and development of transgenic chickens has encountered difficulties and therefore 
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has lagged far behind that of mammalian species [104]. Several new methods that facilitated 
the establishment of transgenic avian species, especially chickens and quail, have been 
developed recently [105]. Besides direct DNA injection into oocysts or into the germinal disc 
of zygotes [106], retroviral gene transfer methods [107, 108] and transposons-based 
techniques [109, 110] have been established to randomly manipulate the germline mostly for 
inserting additional genes. The latest developments in avian transgenesis, including the use 
of transcription activator-like effector nuclease (TALEN)-mediated gene targeting [111], gene 
targeting by homologous recombination in primordial germ cells (PGCs) [112] and the use of 
the CRISPR-Cas9 system [113, 114] have been successfully used to generate targeted gene 
knockout chickens for the first time. With these techniques, the set of applications for 
transgenic avian species as models are expanding in basic scientific research, for novel 
biotechnology approaches as well as to improve productivity in poultry industry [105]. Targeted 
knockout chickens, however, have not been used in infection experiments until now. The use 
of targeted transgenic chickens would tremendously improve our understanding of host factors 
and host cells involved in disease progression and/or host responses that would help to further 
dissect the pathogenesis of various pathogens. Applications of those technologies in 
biomedical research therefore are no longer limited by technological methods and skills, but 
only by creativity and imagination. 
 
6.9  MDV tumors, imaging mass spectrometry and proteome analysis 
The onset of MDV-induced tumor development is relatively rapid. Within 3-4 weeks post 
infection, the virus is able to establish latency, integrate into the host cell chromosomes and 
transform target cells, which then ultimately leads to fatal lymphoma in visceral organs [115]. 
It has been shown that MDV-induced tumors are dominated by a highly restricted number of 
clonal CD4+ T cells [116]. More and more evidence point to a critical role of epigenetic 
regulation such as histone modifications and DNA methylation that facilitate the maintenance 
of viral latency [117, 118]. As described in “6.5 MDV virulence factors”, MDV transcribed 
sequences that are noncoding (vTR, miRNAs) also significantly influence MDV tumorigenesis. 
However, the majority of features that are conductive to the whole latency and transformation 
complex in MDV infections are yet to be deciphered. 
Imaging mass spectrometry (IMS) techniques allow mass spectrometric measurements with 
high resolution. Protein mass spectra are registered in a grid pattern over the analyzed surface 
and the distribution of specific masses can be then visualized. Applied to tissue sections, this 
unique tool can directly link histological structures to mass spectrometric data [119]. The huge 
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advantage of an IMS-based workflow is that it is not restricted to analytes of interest and allows 
an unbiased view on sample material. Furthermore, this technique is not limited to the 
availability of detection probes such as antibodies, fluorescent chromophores or nucleic acids. 
The use of detection probes requires a strong binding affinity for particular targets that enable 
those targets to be detected in a complex sample. This is drastically limited by the availability 
of molecular markers and the issue does not occur in IMS based approaches. On the contrary, 
IMS is not only highly versatile, but also very specific and numerous distinct masses can be 
detected and discriminated at the same time [120]. The IMS-based approach is likely to be 
applicable for the detection of macroscopically undetectable MDV-induced lymphomas and, 
combined with microdissection techniques, allows proteome analyses of snap-frozen and 
formalin-fixed paraffin embedded (FFPE) tumor samples from MDV-infected chickens. 
 
6.10  Project introductions 
Despite of many years of MDV research, many critical questions remain unanswered. This is 
due to a lack of tools and targeted transgenic chickens. In this thesis, we used the first targeted 
knockout chickens to provide novel insights into lymphocyte infections of this oncogenic avian 
herpesvirus. Furthermore, it supplies an overview and a critical evaluation of recent MDV 
literature (particularly from the past 5 years) on MDV virulence factors. Finally, this thesis 
contributes findings from proteomic analyses of pure MDV-induced T cell lymphomas.  
The first paper of this cumulative dissertation determined the role of peripheral and mature B 
cells in MDV pathogenesis. Thanks to recent advances in avian genetics and the use of 
genetically engineered chickens that lack peripheral and mature B cells but still harbor 
immature precursor B cells in the bursa, this data show that B cells are dispensable for disease 
onset, disease progression and viremia, as well as for tumor development. Furthermore, this 
data allows a further refinement of the current model of MDV pathogenesis. The second paper 
is a digest of latest literature that describes novel in vitro and in vivo findings on MDV 
pathogenesis, with an emphasis on viral virulence factors, in form of a systematic review. The 
review combines datasets and summarizes our current understanding of the mechanisms of 
viral factors that are involved in MDV pathogenesis and lymphomagenesis. A deeper 
knowledge of the virus will also provide new strategies for the ultimate goal of our field of 
research: the vaccine development against this deadly poultry pathogen. In the third 
manuscript, an IMS-based pipeline was implemented in order to eventually identify potential 
protein biomarkers in MDV-induced lymphomas. This is a collaborative work with the Friedrich-
Loeffler-Institut (Riems) that provides new insights into the proteomic profile of MDV-
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transformed T cells ex vivo. IMS and subsequent non-contact laser capture microdissection 
(LCM) followed by a proteomic workflow was used as an ‘open view’ tool for MDV-tumor protein 
mass spectrometry (MS). The major objective of that study was to identify protein biomarkers 
that characterize transformed T cells – both in solid MDV-induced tumors and in blood 
samples, but also to establish a technique that allows a proteomic analysis of pure MDV-
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10.1  General discussion 
Marek’s disease is one of the most frequent virus-induced cancers in the animal kingdom 
and has an enormous economic impact on poultry industry worldwide. Like other 
herpesviruses, MDV establishes latency and thereby ensures a life-long infection in its 
natural host, the chicken. As a remarkable feature, MDV maintains its genome in latently 
infected cells by integrating it into the telomeres of host chromosomes. As already mentioned 
and discussed in the previous chapters, this integration event makes MDV such a special 
and intriguing pathogen. MDV shares features with human herpesvirus and serves as a 
model in biomedical science – not only for virus-induced tumor formation. MDV also serves 
as an animal model for research on the role of immune control in herpesvirus infections and 
on factors and mechanisms leading to virus latency [1].  
The MDV infectious life cycle is initiated by the inhalation of cell-free MDV. Macrophages are 
thought to transfer the virus to lymphoid organs such as spleen, thymus and bursa, where 
the virus replicates in B cells and subsequently in T cells. MDV is able to establish latency in 
infected T cells, which then transport the virus to the skin and the feather follicle epithelia, 
where cell free MDV is generated. A hallmark of MDV pathogenesis is its ability to integrate 
into telomeres and thereby transform T cells, which frequently results in tumor formation [2]. 
MDV replicates very efficiently in B cells, which coincides with the initial amplification step 
during infection and leads to high viral titers in the lymphoid organs and to viremia [3-6].  
B cells were thought to play a crucial role in the virus life cycle. The subsequent infection of 
T cells and an accompanying immunosuppression leads to an ensuing onset of clinical 
symptoms and is required for disease onset and tumor development [5, 7-10]. Even though 
B cells are the most frequent cell type infected in vivo, it remained unclear if these cells 
indeed contribute to MDV pathogenesis and a plethora of bursectomy studies failed to 
provide conclusive answers [3, 11-17]. Therefore, the exact role of B cells in the MDV life 
cycle was not elucidated yet. New tools in avian immunology and the development of 
targeted transgenic chickens allowed you to assess the exact role of B cells in MDV. 
MDV is a very efficient and reliable pathogen regarding disease initiation and tumor 
formation. Moreover, with annually 50 to more than 100 scientific papers on MDV, MDV 
research continually progresses. However, there are certain missing links that are needed to 
understand these processes in more detail. A lot is known for viral factors that contribute to 
MDV pathogenesis and especially tumorigenesis; however, there are many aspects that 
102 
  
have not been assessed yet and an update of the status quo combining latest findings helps 
to identify knowledge gaps in order to fill them.  
Moreover, a closer look into MDV lymphomas and differentially regulated proteins in tumor 
tissues takes us a step closer to understanding MDV tumor biology. This was achieved using 
MALDI imaging and laser capture microdissection combined with mass spectrometry [18, 19] 
to visualize MDV tumors and identify tumor markers. 
 
10.1.1  B cells are dispensable for efficient MDV pathogenesis and tumorigenesis 
Our study on the role of B cells in MDV infections (“Unraveling the role of B cells in the 
pathogenesis of an oncogenic avian herpesvirus”), disease and tumor development 
describes the first infection experiment in transgenic knockout birds. I strongly believe that it 
provides an important insight into the role of B cells in MDV, since until now B cells were 
thought to play a vital role in MDV pathogenesis. Using the first targeted knockout chickens 
that lack peripheral and mature B cells, we could break this dogma and demonstrate that  
B cells are completely dispensable not only for lytic replication and spread in the host, but 
also for disease and tumor development. The genetic background of the chickens used to 
generate the JHKO birds were found to be more resistant to very virulent MDV. This explains 
the low MD and tumor incidences in naturally infected birds that were housed as sentinels 
with the experimentally infected JHKO chickens. Furthermore, an age-related resistance to 
MDV infections adds up to these data. Shedding of MDV only occurs after 14 dpi. and at that 
age, the JHKO chickens were even more resistant than directly post hatch. Of note is that 
the delayed arrival of virus in the spleen and the thymus could point to only a minor role of B 
cells in early MDV replication. However, our data will refine the current model of the MDV life 
cycle and furthermore pioneer the use of knockout chickens in infectious disease research. 
Furthermore, CD4+ and CD8+ T cells were also found to complement for the B cell loss in  
4 dpi tissue samples. In these organs, however, the general infection rate was too low to 
make firm conclusions. Nevertheless, it is very clear that as long as enough T cells and/or 
the right T cell is infected, tumors are induced by MDV. 
Follow-up questions for further research would definitely include the recruitment of those 
CD4+ and CD8+ T cells: how does the virus enter the T cells if B cells are not around? Does 
vIL-8 recruitment, that was shown to be effective for B cells and CD4+ CD25+ T cells [10], 
also apply to CD8 T cells? In an MDV in vitro integration assay (discussed below), we show 
that the virus can readily infect different chicken T cell lines. This in vitro assay, combined 
with binding, flow cytometry- and chemotaxis assays could elucidate vIL8 involvement in 
CD8 T cell infections. Furthermore, it would be more than interesting to evaluate the 
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contribution of immature bursal B cells to viremia. Since we found AV20+, MDV infected 
progenitor B cells in the bursal tissue samples of homozygous knockout chickens, these cells 
could very well facilitate productive infection and produce virus to be disseminated. However, 
the majority of infected cells in bursal tissue samples of homozygous knockout chickens were 
CD4+ and CD8+ T cells. This shows that the progenitor B cells are not as susceptible to 
MDV infection as compared to mature B cells in bursal tissues of heterozygous birds (Fig. 
13). 
The further use and applications of genetically modified chickens in both biomedical research 
and poultry production is not limited by techniques and technical skills anymore – only by 
creativity and innovativeness (and funding). Exemplarily, targeted knockouts in chickens 
have been used to study B cell development using light chain knockout chickens [20]. 
Furthermore, chickens expressing the Cre recombinase are used to study (trans-) gene 
expression [21] and of course, the CRISPR/Cas9 system is currently introducing a variety of 
















10.1.2 The Cornell model revised  
With the new insights into MDV pathogenesis and the MDV life cycle using B cell less 
chickens, we propose a refinement of the current model of the MDV life cycle (Fig. 18). 
 
Figure 19: Proposed model of MDV infection 
I propose that an MDV infection starts with the inhalation of cell-free MDV. 
Macrophages transfer the virus to lymphoid organs such as spleen, thymus and bursa, 
where the virus lytically replicates in those macrophages, but also in B cells, T cells and 
NK cells. MDV is able to establish latency in infected T cells, which then transport the 
virus to the skin and the feather follicle epithelia (FFE), where cell free MDV is 
generated. 
 
It is true that there is a strong lytic infection of B cells [3, 25], but other immune cells are 
equally well infectable and could therefore contribute to initial viremia and high viral titers in 
the lymphoid organs. This hypothesis is supported by findings describing lytic infections in 
macrophages and dendritic cells [26]. Furthermore, NK cells support lytic MDV replication 
(Christine Jansen, unpublished data) and even T cells, the primary target cell for latent 
infections, are prone to the lytic stages [25]. A virus silencing through latency establishment 
and subsequent T cell transformation then leads to lymphoma development. However, to 
dissect the different target cells entirely, more in vivo data has to be generated and in vivo 
imaging tools could help to address these questions. 
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10.1.3  MDV encodes several genes involved in pathogenesis and tumorigenesis 
Regarding MDV virulence factors, a lot is known (but a lot is not). In our review article “Viral 
factors involved in Marek’s disease virus (MDV) pathogenesis”, we describe and discuss the 
major players that orchestrate MDV pathogenesis. Most of the known MDV genes have 
homologues in other alphaherpesviruses, particularly in HSV-1. They often play important 
roles in DNA replication and various other processes essential for the virus lifecycle. MDV 
also encodes some specific genes, known to play central roles in the disease establishment 
and disease progression. In our review, we discuss MDV-encoded proteins, RNAs, and 
sequence elements that efficiently contribute to MDV pathogenesis. Factors that were not 
part of the manuscript, including vLIP, gC, US3p or UL49.5p, were not discussed because 
research data on those proteins is very limited and their contribution to MDV pathogenesis 
are of indirect nature or of minor interest to the field. The viral lipase homolog (vLIP) gene 
encodes for a secreted glycoprotein that was found to contribute to efficient viral replication 
in infected cells. vLIP mutant viruses caused a significantly lower disease incidence in 
experimentally infected chickens [27]. The MDV glycoprotein C (gC) has multiple splice 
variants and is essential for the horizontal transmission of the virus [28, 29]. The MDV-
encoded serine/threonine protein kinase US3 involved in virus cell-to-cell spread [30] and a 
non-glycosylated transmembrane protein termed UL49.5 was shown to down-regulate 
surface expression of MHC class I [31] and cell-to-cell spread [32]. Since the MDV research 
community is rather small and performance of high throughput methods are only starting to 
be applied to the virus, I strongly believe that more virulence factors will be uncovered and 
that this could lead to recognition of new targets for vaccine development. 
 
10.1.4 Mass spectrometric techniques reveal potential MDV tumor markers 
As a new tool in the MDV research toolbox, an IMS-based approach was used to visualize 
MDV tumors, identify changes in protein expression during the MDV transformation process 
and find possible tumor markers. For that, MDV-induced tumors from different recombinant 
viruses were subjected to a workflow that allows an in situ molecular mapping of 
characteristic protein mass signatures. These regions were micro-dissected and applied to 
a LC-MALDI TOF/TOF mass spectrometric pipeline. In total, we found 19 proteins that were 
up- or downregulated in MDV tumors as compared to primary chicken T cells and uninfected 
tissue controls. These proteins were not strongly regulated, suggesting that MDV is a rather 
silent invader. Nonetheless, the identified potential transformation markers were employed 
in a gene ontology (GO) term enrichment analysis and were found to be associated with five 
pathways: (i) nucleosome assembly, (ii) regulation of transcription, (iii) inflammatory 
response, (iv) immune response, and (v) oxidation-reduction process. As a confirmation, 
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RNAs of randomly selected transformation markers were validated by qPCR. To confirm that 
they are indeed markers for MDV-induced transformation, further functional analyses are 
needed. Additionally, the identification of protein profiles in cells of different stages of latency 
and transformation would unravel further details. For this, in vivo time-course experiments 
would be necessary. Considering that it is impossible to synchronize infections of CD4+  
T cells in chickens this remains very challenging. As a follow-up on the tumor imaging and 
proteome analysis manuscript, we are also looking into the transcriptional and translational 
profile of MDVs target cells for lytic replication in vivo. Here, we made use of whole 
transcriptome shotgun sequencing, mass spectrometry and protein profiling, and microarray 
technologies to identify MDV transcripts and MDV proteins expressed in lytically infected B 
cells comparing the very virulent MDV field strain RB1B and the MDV vaccine  
CVI-988/Rispens. We are currently analyzing these data sets and will submit the manuscript 
soon. 
 
10.2  Final remarks and outlook 
During my PhD in the Viral Integration and Tumorigenesis Group at the Institute of Virology, 
I worked on different projects that all focused Marek’s disease virus-host interplay with a 
special emphasis on lymphocyte infections. Exceeding the three manuscripts of this doctoral 
thesis, I have been working on several other projects that strongly link to these projects in 
terms of content: As one of many groups that work on MDV, we also work on the development 
of novel MDV vaccines. As MDV vaccines have been shown to induce mild 
immunosuppression and hence, reduce an immune response against other pathogens, this 
immunosuppression also leads to an increased susceptibility to E.coli and possibly other 
pathogens [33, 34]. Chickens are probably one of the most vaccinated animal species today 
and MDV-induced immunosuppression with a subsequent reduction of vaccine responses 
could reduce the efficacy of many vaccines that are applied to chickens early in life. 
Additionally, MDV field strains can still circulate in MDV-vaccinated birds and that might 
likewise induce immunosuppression in these animals, even if they do not develop Marek’s 
disease symptoms. Therefore, there is a need for novel vaccines that do not suppress the 
chicken immune system. Recent work from our laboratory shows that the MDV-encoded 
chemokine vIL-8 facilitates the recruitment of B cells and CD4+ CD25+ T cells to the site of 
infection [10]. A productive and lytic virus replication in the recruited cells causes severe 
lymphocyte reduction [5]. Therefore, an abrogation of the chemokine expression by start 
codon mutation in CVI988, the gold standard vaccine strain, should reduce the number of 
lymphocytes that are recruited, infected, and killed by MDV. In addition, we made use of a 
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previously reported vaccine candidate that lacks the major oncogene meq (Δmeq) and has 
an enhanced vaccine protection against highly pathogenic MDV strains compared to other 
commercial vaccines. This Δmeq mutant still induces severe thymus atrophy [35]. 
Introduction of a vIL8 start codon mutation, which leads to abrogation of the protein in this 
virus background, likely reduces or eliminates the aforementioned immunosuppressive 
effect. That could result in a vaccine that provides an enhanced protection without the 
negative side effects. As a last set of vaccine candidates, two viruses that harbor a mutation 
in the template sequence of viral telomerase RNA (vTR) were generated in RB1B (by Kaufer 
et al. [36]) and in CVI. The RB1B vaccine candidate was tested in vivo and not only abrogates 
virus-induced tumor formation but also reduces the number of infected lymphocytes via the 
elimination of MDV infected cells. I constructed and successfully obtained virus stocks of the 
same mutation in the CVI background. These novel vaccine candidates will be tested in vivo 
soon. This work links to the review article “Viral factors involved in Marek’s disease virus 
(MDV) pathogenesis” with real life applications and could be a step forward in the 
prophylactic treatment of MDV in field conditions. Furthermore, some of the vaccine 
candidate viruses are currently under investigation regarding their ability to infect and 
activate NK cells in collaboration with the group of Dr. C. A. Jansen (Avian Immunology 
Group, Faculty of Veterinary Medicine, Utrecht University, NL). A detailed understanding of 
the contribution of other cell types, such as NK cells, to the MDV-induced 
immunosuppression can close knowledge gaps and thereby facilitate a more focused and 
goal-oriented development of novel MDV vaccines. As another data set that will contribute 
new insights, some of the vaccine viruses will be used in in vitro studies of cell death/cell 
survival in primary B cell cultures in collaboration with the group of PD Dr. Sonja Härtle 
(Institute for Animal Physiology, Ludwig-Maximilians-Universität München). In order to 
broaden the tools for in vitro studies in MDV research, we also set to establish an MDV in 
vitro integration assay. Until now, the investigation of the MDV integration mechanism 
required animal experiments due to the lack of an in vitro integration assay. With the 
establishment of an in vitro integration assay using immortalized chicken T cell lines, the 
latent infections, integration and transformation of MDV can be studied in vitro. Using 
quantitative PCR and the fluorescence in situ hybridization (FISH) technique will allow a 
quantitative evaluation of MDV maintenance and genome integration. With this, the 
mechanism that allows MDV to maintain its virus genome during latency and to induce deadly 
lymphomas can be further investigated. Potential viral and cellular factors that could be 
involved in these processes can be unraveled which would link this study to the review article 
on viral virulence factors. Potential viral factors in T cell transformation are the different MDV 
TMRs (as mentioned), but also the viral DNA polymerase UL30 [37], UL29 (a single strand 
DNA binding protein) and UL12, a 5’-3’ exonuclease [38]. We are currently also assessing 
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integration of the different MDV vaccines (CVI988/Rispens, SB-1, HVT) and the role of their 
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Marek’s disease virus-host interplay: novel insights into lymphocyte infections of an 
oncogenic avian herpesvirus. 
Marek's disease is a highly contagious lymphoproliferative disorder of chickens caused by 
an oncogenic and strictly cell-associated alphaherpesvirus known as Marek’s disease virus 
(MDV). MDV is prevalent worldwide and causes fatal lymphomas in the chicken, resulting in 
a high economic burden. Despite the widespread use of live attenuated vaccines, MDV 
remains a major pathogen of poultry and continues to be a threat to poultry health and 
welfare. It has been widely assumed that MDV initially infects B cells, which are the primary 
target cells in an infected chicken. MDV is then subsequently passed to T cells where it is 
able to establish a latent infection by integrating its genome into the host telomeres. This 
integration is a prerequisite for T cell transformation, tumorigenesis and a fatal outcome for 
the infected chicken.  
The complex viral processes underlying MDV infections in poultry leading to T cell 
transformation and lymphomagenesis involve a plethora of viral factors ranging from viral 
proteins to non-coding RNAs. In order to further our understanding of MDV pathogenesis, I 
set out to define the exact contribution of specific lymphocytes towards MDV pathogenicity 
in vivo and uncover the proteomic makeup of MDV-transformed cells. Furthermore, this 
thesis presents an up-to-date review on the advances in MDV research with a specific focus 
on its virulence factors.  
To directly assess the role of B cells in MDV pathogenesis, I utilized the first targeted 
knockout chickens (JH-KO) that lack mature and peripheral B cells in an in vivo MDV 
challenge study. These data broke the dogma regarding the vital role of B cells in MDV 
pathogenesis, and demonstrated that they are completely dispensable for virus replication, 
spread in the host, disease and tumor development. Moreover, it was shown that CD4+ and 
CD8+ T cells complement for the loss of B cells in JH-KO chickens in terms of virus 
amplification and virus spread in the host.  
Secondly, advances in tumor imaging and mass spectrometry allowed acquisition of MDV-
tumor proteomic data. This thesis describes the establishment and implementation of an 
imaging mass spectrometry (IMS)-based pipeline that was used to identify potential protein 
biomarkers of MDV-induced lymphomas. IMS and subsequent non-contact laser capture 
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microdissection of MDV lymphoma was followed by a proteomic workflow and provides an 
unbiased ‘open view’ tool for protein mass spectrometry of MDV-induced tumors.  
Lastly, this thesis provides a review of all recent literature and advances in MDV research on 
virus virulence factors. This summarizes the current scientific consensus of how viral factors 
contribute to MDV-induced pathogenesis and tumor formation. Several important viral factors 
involved in MDV pathogenesis have been discussed, including the major oncoprotein Meq, 
the viral chemokine vIL-8, MDV-encoded microRNAs, RLORF4, RLORF5a, pp14, pp38, a 
virus-encoded telomerase RNA, and viral telomeric repeats.  
Overall, this thesis contributes towards a greater understanding of MDV pathogenesis, 
shedding light on the cell types involved in virus replication and spread in vivo and factors 






Das Zusammenspiel des Virus der Marek‘schen Krankheit mit dem Wirt: neue 
Einsichten in Lymphozyteninfektionen eines onkogenen aviären Herpesvirus‘. 
Die Marek’sche Krankheit ist eine hochinfektiöse und lymphoproliferative Erkrankung der 
Hühner und wird durch eine Infektion mit dem onkogenen und strikt zellassoziierten 
Alphaherpesvirus der Marek’schen Krankheit (Marek’s disease virus, MDV) ausgelöst. MDV 
ist weltweit prävalent und verursacht tödliche Lymphome in Hühnern, was zu hohen 
wirtschaftlichen Verlusten führt. Trotz des weit verbreiteten Einsatzes von attenuierten 
Lebendimpfstoffen ist MDV weiterhin ein wichtiger Infektionserreger und ein Risiko für 
Tiergesundheit und Tierwohl in der Geflügelhaltung. In vivo infiziert MDV sehr effizient  
B Zellen, Zellen die lange als essentiell für eine Virusamplifikation im infizierten Wirt galten. 
MDV wird dann auf T Zellen übertragen, in welchen das Virus eine latente Infektion etablieren 
und das Virusgenom in die Telomere der Wirtszelle integrieren kann. Diese Integration des 
Genoms ist Voraussetzung für die T Zell Transformation, für die Tumorentstehung und für 
den tödlichen Verlauf der Erkrankung im infizierten Huhn.  
Die komplexen viralen Mechanismen die zur MDV Pathogenese und Tumorgenese 
beitragen, beziehen eine Vielzahl viraler Faktoren von Proteinen bis hin zu nichtcodierenden 
Ribonukleinsäuren mit ein. Um das generelle Verständnis von der MDV Pathogenese 
voranzubringen, beschreibt diese Dissertation neue Einblicke in die Beteiligung von 
spezifischen Lymphozyten an der MDV Pathogenität in vivo und deckt das Proteom von 
MDV-transformierten Zellen auf. Zusätzlich beinhaltet diese Dissertation den neusten Stand 
der MDV Forschung in Form einer systematischen Übersichtsarbeit, mit einem speziellen 
Fokus auf die viralen Virulenzfaktoren.  
Um die Rolle von B Zellen in der Krankheitsentstehung und -entwicklung zu beurteilen, 
konnte ich die ersten transgenen Knockouthühner (JHKO), welche keine ausgereiften und 
peripheren B Zellen mehr aufweisen, in einem in vivo Infektionsversuch nutzen. Diese Daten 
brechen mit dem Dogma der zentralen Rolle von B Zellen in der MDV Pathogenese und 
zeigen, dass B Zellen für die Virusreplikation, die Ausbreitung im infizierten Wirt und auch 
für Krankheits- und Tumorentstehung komplett entbehrlich sind. Darüber hinaus wurde 
gezeigt, das CD4+ und CD8+ T Zellen für die Inexistenz von B Zellen in JHKO Hühnern in 
Bezug auf Virusamplifikation und Ausbreitung des Virus im Wirt kompensieren.  
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Fortschritte in der Tumorbildgebung und der Massenspektrometrie erlauben die Erfassung 
von MDV Tumor-Proteomdaten. Die vorliegende Dissertation beschreibt die Etablierung und 
die Umsetzung einer auf der massenspektrometrischen Bildgebung (imaging mass 
spectrometry, IMS) basierenden Pipeline, die genutzt wurde um mögliche MDV 
Tumormarkerproteine zu identifizieren. IMS und subsequente berührungslose Laser 
Mikrodissektion (non-contact laser capture microdissection) von MDV Tumoren gefolgt von 
einem proteomischen Workflow stellt hier eine unvoreingenommene Möglichkeit 
proteinmassenspektrometrischer Untersuchungen an MDV Tumoren dar.  
Zuletzt bietet diese Dissertation ein Review der gesamten Literatur und der Fortschritte 
bezüglich viraler Virulenzfaktoren in der MDV Forschung der letzten Jahre. Das Review fasst 
die derzeitige Lehrmeinung hinsichtlich viraler Faktoren in der MDV-induzierten 
Pathogenese und Tumorgenese zusammen. Mehrere wichtige virale Faktoren, die in die 
Krankheitsentstehung involviert sind, wurden hier diskutiert. Dazu gehören das 
Hauptonkogen Meq, das virale Chemokin vIL8, MDV-codierte microRNAs, RLORF4, 
RLORF5a, pp14, pp38, eine viruscodierte Telomerase RNA und virale, sich wiederholende 
Telomerregionen.  
Zusammenfassend trägt diese Dissertation zu einem besseren Verständnis der MDV 
Pathogenese bei, indem sie neben der Rolle von Zellen, welche die Virusreplikation und die 
Virusausbreitung im Wirt in vivo ermöglichen, auch Proteinbiomarker in MVD-induzierten 
Tumoren beschreibt.  
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